Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Daiichi Sankyo Invests €1 Billion in Munich Site | Contract Pharma

What are you searching for?

Sign in
Breaking News

Daiichi Sankyo Invests €1 Billion in Munich Site

Expansion will add capacity to make cardiovascular drugs and labs to develop and produce antibody drug conjugates (ADCs).

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Daiichi Sankyo has announced plans to invest approximately $1.07 billion to expand a site near Munich, Germany, to boost its work on precision cancer drugs.
 
Reuters reports, the investment was announced as health minister Karl Lauterbach visited the center in Pfaffenhofen, north of Daiichi’s European headquarters in Munich.
 
The project will create 350 jobs by 2030 and will add capacity to make cardiovascular drugs and labs to develop and produce antibody drug conjugates (ADCs).
 
This news comes months after Depixus entered a collaboration with Daiichi Sankyo to use their novel MAGNA technology to accelerate Daiichi’s RNA-targeted drug discovery program.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics